4yr
Sacituzumab shows modest benefit compared to standard chemotherapy in HR-positive patients treated with 2-4 prior lines of chemotherapy. Here is Hope Rugo discussing these findings:
-
Breast Cancer Connect4yrWhat has been your experience with sacituzumab in HR-positive patients who received prior chemo?
-
Albert Dekker4yrtoxicity is an issue and Irinotecan was never a highly effective agent in ER+ breast cancer
-
Sarah Mougalian, Yale Cancer Center4yr